AbbVie revenues and earnings up 18%; Non-GAAP EPS up 17% in Q2; updates guidance

• AbbVie (NYSE:ABBV +1.7%) Q2 results: Total Revenues: $6,432M (+17.5%); U.S.: $4,100M (+21.7%); Intl: $2,332M (+10.8%).
• Net Income: $1,610M (17.9%); EPS: $0.98 (+18.1%); Non-GAAP EPS: $1.26 (+16.7%).
• Key Product Sales: Humira: $4,149M (+17.4%); Viekira: $419M (+9.1%); Imbruvica: $439M; Synagis: $45M (-2.6%); Lupron: $219M (+10.4%).
• 2016 Guidance: EPS: $3.82 - 3.92; Non-GAAP EPS: $4.73 - 4.83 from $4.62 - 4.82.